Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK

Das, Ira; Nightingale, Peter; Patel, Mahesh; Jumaa, P.

doi:10.1016/j.ijid.2011.06.006

Cited by 123 publications

(147 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is similar to the incidence rates published by other groups in our country (Colombo et al 2007, França et al 2008, Girão et al 2008, Nucci et al 2010), but consistently higher than studies conducted in the northern hemisphere. Epidemiological studies performed in tertiary care hospitals in Europe and the United States have shown incidence rates ranging from 0.02-1.08 cases per 1,000 hospital admissions (Hajjeh et al 2004, Tortorano et al 2004, Almirante et al 2005, Zilberberg et al 2008, Poikonen et al 2010, Arendrup et al 2011, Das et al 2011.…”

Section: Discussionmentioning

confidence: 99%

“…The incidence rate of candidaemia continues to be high, with incidence rates ranging from 1.27-2.49 per 1,000 admissions (Colombo et al 2006, França et al 2008, Girão et al 2008, Motta et al 2010, Pereira et al 2010. Conversely, studies undertaken in tertiary hospitals in the United States and several European countries have shown lower incidence rates, ranging from 0.28-0.96 and 0.02-1.08 per 1,000 admissions, respectively (Hajjeh et al 2004, Tortorano et al 2004, Almirante et al 2005, Zilberberg et al 2008, Poikonen et al 2010, Arendrup et al 2011, Das et al 2011 .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Historical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil

Wille¹,

Guimarães²,

Furtado

et al. 2013

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Historical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil

Wille¹,

Guimarães²,

Furtado

et al. 2013

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…La incidencia de candidemia en nuestro centro resultó menor a la publicada en estudios epidemiológicos, tanto de países de Latinoamérica como de otros continentes 6,9,10 . Respecto a los datos latinoamericanos reportados por Nucci y cols.…”

Section: Discussionunclassified

“…En su mayoría, la candidemia representó un evento tardío dentro de la tercera semana de hospitalización y más de la mitad de los casos se encontraban en UPC al momento del diagnóstico. Todos estos aspectos son similares a lo antes publicado en la literatura internacional 2,8,10 .…”

Section: Discussionunclassified

Cambios clínicos y epidemiológicos de candidemias en pacientes adultos desde 2000 a 2013

Siri

Legarraga

García

et al. 2017

Rev. chil. infectol.

View full text Add to dashboard Cite

60 years, 77,5% had at least one co-morbidity. Candida albicans was the species most frequently identified 55%, followed by C. glabrata 18.3%, C. tropicalis 11.7% and C. parapsilosis 9.2%. Comparing 2000-2006 vs 2007-2013, increased the frequency of C. parapsilosis among non-albicans and echinocandins prescription. Patients with C. albicans showed higher APACHE-II, more requirement for invasive mechanical ventilation, greater association with CVC, and shorter incubation time compared with non-albicans species. The 30-day mortality was 31.7%. Conclusions: During this 14-years period we observed that C. albicans was the predominant specie and more recently a change among C. non-albicans increasing C. parapsilosis and decreasing C. glabrata 30-days and attributable mortality decreased together with more echinocandins prescription.]]>

show abstract

“…Currently, other species of this genus have been found to cause an increasing number of cases of candidiasis (Mokaddas et al, 2007;Pereira et al, 2010;Das et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

In vitro antifungal activity of the flavonoid baicalein against Candida species

Serpa

França

Furlaneto-Maia

et al. 2012

Journal of Medical Microbiology

View full text Add to dashboard Cite

The aim of the present study was to evaluate the in vitro activity of baicalein, the flavone constituent of Scutellaria baicalensis, and synergism of the combination of baicalein and fluconazole against Candida albicans, Candida tropicalis and Candida parapsilosis. The MIC 50 (lowest concentration at which there was 50 % inhibition of growth) of baicalein alone against six Candida strains ranged from 13 to 104 mg ml "1 . For the three species tested, exposure to baicalein at the MIC 50 concentrations obtained for each strain resulted in a high loss of viability. The fluconazole plus baicalein combination markedly reduced the MICs of both drugs for all three strains analysed. In addition, a synergistic effect between baicalein and fluconazole was observed for C. parapsilosis in terms of MIC 50 (fractional inhibitory concentration index50.207). Scanning electron microscopy analysis revealed that yeast cells exposed to baicalein at MIC 50 produced a profusely flocculent extracellular material, resembling a biofilm-like structure. In conclusion, these results showed the antifungal capability of baicalein against Candida species and highlight a promising role of baicalein when used in combination with fluconazole against Candida infections. INTRODUCTIONCandidiasis is one of the most common fungal infections in humans caused by Candida species, most notably by Candida albicans. Currently, other species of this genus have been found to cause an increasing number of cases of candidiasis (Mokaddas et al., 2007;Pereira et al., 2010;Das et al., 2011).The therapy of invasive candidiasis remains a difficult medical problem. Despite the availability of extendedspectrum triazoles, the incidence of invasive infections and resistance to antifungal therapy continue to increase (Pfaller & Diekema, 2010). Widespread use of antifungal agents could be an explanation for the emergence of the more resistant non-albicans species of Candida, such as Candida glabrata (reviewed by Kothavade et al., 2010; Silva et al., 2012).The azole fluconazole is effective against most Candida species and is used currently as a first-line drug, although different degrees of susceptibility among species have been described. For instance, C. glabrata is inherently less susceptible to fluconazole. In addition, the emergence of fluconazole resistance has been reported in species typically susceptible to this agent, such as C. albicans, Candida tropicalis and Candida parapsilosis (Hajjeh et al., 2004;Yang et al., 2004;Lyon et al., 2010;Oxman et al., 2010; Arendrup et al., 2011), including that observed in Brazilian tertiarycare hospitals (Bruder-Nascimento et al., 2010;Favalessa et al., 2010;Pereira et al., 2010;Furlaneto et al., 2011).These factors present an urgent need to search for novel compounds with anticandidal activity. To this end, efforts have been made in the search for novel antifungal agents from various natural sources. In this regard, baicalein (5,6,7-trihydroxyflavone; Fig. 1) is a flavonoid originally isolated from the roots of the Chine...

show abstract

Epidemiology, clinical characteristics, and outcome of candidemia: experience in a tertiary referral center in the UK

Abstract: Candidemia continues to be associated with a high mortality. Preventative measures should be targeted against high-risk hospitalized patients, especially those in ICUs, the elderly, and those undergoing major surgery. Local surveillance of candidemia is important to optimize management.

Cited by 123 publications

References 24 publications

Historical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil

Historical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil

Cambios clínicos y epidemiológicos de candidemias en pacientes adultos desde 2000 a 2013

In vitro antifungal activity of the flavonoid baicalein against Candida species

Contact Info

Product

Resources

About